Pharmaceutical Executive - "Pharma in the Dell: Working with Academia"

 – November 14, 2012 /Press Release/  –– 

How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai School of Medicine discussed ways to bridge the gap, and the growing importance of data across all business areas. In his keynote speech at Mount Sinai's SinaInnovations conference, Jeffrey Hammerbacher, formerly head of Facebook's data team and co-founder of Cloudera, an open-source software firm, said healthcare is witnessing a "manifest destiny for data," which will expand not from sea to shining sea, but from "atom to shining bit." Ever-growing data sets and analytics are coming, so companies can either "ride the wave or complain about it, and get washed up." Hammerbacher, who recently joined Mount Sinai School of Medicine as an assistant professor, also stressed the importance of failure. The three-day SinaInnovations conference was held at Mount Sinai School of Medicine in New York City. Learn more